Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 生物股份 |
|---|---|
| Other Market Stock Code | 600201 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Cansinobio |
|---|---|
| Stock Code | 06185 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事研發疫苗產品。 |
| Listing Date | 2019-03-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國天津市經濟技術開發區西區南大街185號西區生物醫藥園四層401-420 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.cansinotech.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 22.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 28.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 503,791,200 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|---|
| Analysis Result | Already included in Stock Connect (both, shenzhen, shanghai) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 34.7 |
|---|---|
| First Day Open | HK$ 30.5 |
| First Day Change | 57.73% |
| First Day Volume | 25930000.0 |
| First Day Turnover | 820373000.0 |
Use of Proceeds
| Use of Proceeds | 1、約80%（或920.7百萬港元）將用于我們核心產品以及我們疫苗產品線中其他主要產品的研發及商業化； 2、約10%（或115.1百萬港元）將用于臨床前在研疫苗的持續研發； 3、約10%（或115.1百萬港元）將用于營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (3)
Joint Bookrunners (5)
Joint Lead Managers (5)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | LAV Amber Limited | 78,478,400 HKD | — | 6.23% | — | 6 months | 2019-09-28 |
| 2 | Worldwide Healthcare Trust PLC | 196,200,400 HKD | — | 15.58% | — | 6 months | 2019-09-28 |
| 3 | 津联卓睿投资有限公司 | 78,478,400 HKD | — | 6.23% | — | 6 months | 2019-09-28 |
Directors & Management
| Chairman | 宇學峰 |
|---|---|
| Company Secretary | 崔進,趙明璟 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Yu Xuefeng及關連人士(31.19%) |
|---|
